Alexandre González-Rodríguez1, Oriol Molina-Andreu2, María Luisa Imaz Gurrutxaga3, Rosa Catalán Campos4, Miquel Bernardo Arroyo5. 1. Servicio de Psiquiatría, Hospital Clínic de Barcelona, Barcelona, España. Electronic address: alexgonzalezrguez@gmail.com. 2. Servicio de Psiquiatría, Hospital Universitari Mútua de Terrassa, Terrassa, España. 3. Servicio de Psiquiatría, Hospital Clínic de Barcelona, Barcelona, España. 4. Servicio de Psiquiatría, Hospital Clínic de Barcelona, Barcelona, España; Unidad de Esquizofrenia, Instituto Clínico de Neurociencias, Hospital Clínic de Barcelona, Barcelona, España. 5. Servicio de Psiquiatría, Hospital Clínic de Barcelona, Barcelona, España; Unidad de Esquizofrenia, Instituto Clínico de Neurociencias, Hospital Clínic de Barcelona, Barcelona, España; Departamento de Psiquiatría y Psicobiologia Clínica, Universitat de Barcelona, Barcelona, España; Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España; Centro de Investigación Biomèdica en Red de Salud Mental (CIBERSAM), España.
Abstract
INTRODUCTION: Gender differences in attendance rates for appointments in delusional disorder have been poorly studied. Furthermore, delusional disorder is traditionally considered a treatment-resistant disorder. MATERIAL AND METHODS: We conducted a longitudinal retrospective study with a one-year follow-up, including 78 delusional disorder patients (DSM-IV-TR), consecutively admitted over a period of 10 years. We performed a follow-up for one year in order to describe demographic and clinical variables, and to compare the therapeutic effectiveness. In this study, due to the non-interventional nature of this study, indirect measures were used to measure treatment effectiveness. The sample was divided into three groups according to the antipsychotic received at the first admission. RESULTS: Twenty-three patients received Risperidone Long-Acting Injection (RILD), 30 oral risperidone, and 25 patients received other oral atypical antipsychotics. Delusional disorder women had a later age at onset and needed a longer duration of hospitalization. No statistically significant differences were found between the three treatment groups as regards demographic data, social and personal functioning, and psychopathology at admission. The RILD group showed higher maintenance rates at the end of the follow-up period. Furthermore, the RILD group required treatment with antidepressants and benzodiazepines less often. CONCLUSIONS: We concluded that treatment with RLAI may increase maintenance rates at follow-up in DD patients when compared with other oral atypical antipsychotics.
INTRODUCTION: Gender differences in attendance rates for appointments in delusional disorder have been poorly studied. Furthermore, delusional disorder is traditionally considered a treatment-resistant disorder. MATERIAL AND METHODS: We conducted a longitudinal retrospective study with a one-year follow-up, including 78 delusional disorderpatients (DSM-IV-TR), consecutively admitted over a period of 10 years. We performed a follow-up for one year in order to describe demographic and clinical variables, and to compare the therapeutic effectiveness. In this study, due to the non-interventional nature of this study, indirect measures were used to measure treatment effectiveness. The sample was divided into three groups according to the antipsychotic received at the first admission. RESULTS: Twenty-three patients received Risperidone Long-Acting Injection (RILD), 30 oral risperidone, and 25 patients received other oral atypical antipsychotics. Delusional disorderwomen had a later age at onset and needed a longer duration of hospitalization. No statistically significant differences were found between the three treatment groups as regards demographic data, social and personal functioning, and psychopathology at admission. The RILD group showed higher maintenance rates at the end of the follow-up period. Furthermore, the RILD group required treatment with antidepressants and benzodiazepines less often. CONCLUSIONS: We concluded that treatment with RLAI may increase maintenance rates at follow-up in DD patients when compared with other oral atypical antipsychotics.
Authors: Karishma R Kulkarni; Rashmi Arasappa; Krishna M Prasad; Amit Zutshi; Prabhat K Chand; Kesavan Muralidharan; Pratima Murthy Journal: Prim Care Companion CNS Disord Date: 2016-02-04
Authors: Thomas P White; Rebekah Wigton; Dan W Joyce; Tracy Collier; Alex Fornito; Sukhwinder S Shergill Journal: Neuropsychopharmacology Date: 2015-09-09 Impact factor: 7.853
Authors: Karishma R Kulkarni; Rashmi Arasappa; M Krishna Prasad; Amit Zutshi; Prabhat K Chand; Pratima Murthy; Kesavan Muralidharan Journal: Indian J Psychol Med Date: 2017 Mar-Apr